GPX4 and metabolic dysfunction-associated steatohepatitis: Combining iron chelation with other ferroptosis-modulating approaches, such as GPX4 inhibition, may enhance therapeutic precision and address the multifactorial nature of diseases like NASH and colorectal cancer [71].